Axa S.A. Sells 6,730 Shares of Haemonetics Co. (NYSE:HAE)

AXA S.A. reduced its position in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,400 shares of the medical instruments supplier's stock after selling 6,730 shares during the quarter. AXA S.A. owned 0.10% of Haemonetics worth $4,013,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Boston Trust Walden Corp lifted its position in Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier's stock worth $71,500,000 after buying an additional 106,114 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Haemonetics in the fourth quarter worth $319,000. Pacer Advisors Inc. raised its holdings in shares of Haemonetics by 36.1% during the fourth quarter. Pacer Advisors Inc. now owns 10,104 shares of the medical instruments supplier's stock worth $789,000 after acquiring an additional 2,680 shares in the last quarter. Norges Bank purchased a new stake in shares of Haemonetics during the fourth quarter worth $32,803,000. Finally, Voya Investment Management LLC grew its stake in Haemonetics by 820.5% in the fourth quarter. Voya Investment Management LLC now owns 316,952 shares of the medical instruments supplier's stock valued at $24,748,000 after purchasing an additional 282,521 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Wall Street Analyst Weigh In

HAE has been the subject of a number of recent research reports. Bank of America downgraded Haemonetics from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. Raymond James reaffirmed a "strong-buy" rating and set a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a research report on Friday. Barrington Research reduced their target price on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC dropped their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, JMP Securities reduced their price objective on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Stock Performance

HAE stock traded down $1.50 during midday trading on Tuesday, hitting $68.73. 53,410 shares of the company traded hands, compared to its average volume of 693,082. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $97.97. The stock has a market capitalization of $3.45 billion, a price-to-earnings ratio of 27.06, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The business has a 50 day simple moving average of $62.81 and a 200-day simple moving average of $71.32.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics's revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business posted $0.90 EPS. As a group, equities research analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.